Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A new androgen receptor antagonist has been approved for the treatment of late-stage prostate cancer. Enzalutamide was approved 3 months ahead of schedule due to a priority review by the FDA. The drug is comarketed by Astellas Pharma and Medivation as Xtandi.

Pharmacology Update: Enzalutamide Capsules (Xtandi®)